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Nuclear factor-kappa B (NF-kB) is a transcription factor with high transcriptional activity in cancer cells. In this study, we developed a
novel enhancer–promoter system, kB4-CEA205, in which the basal carcinoembryonic antigen (CEA) promoter sequence (CEA205)
was placed downstream of the four tandem-linked NF-kB DNA-binding sites (kB4). In combination with a kB4 enhancer, the
transcriptional activity of the CEA promoter was significantly enhanced (three- to eight-fold) in cancer cell lines but not in normal cells.
In cancer cell lines, the transcriptional activity of kB4-CEA205 was comparable with that of the SV40 promoter. We also constructed
vectors in which the thymidine phosphorylase (TP) cDNA was under the control of CEA205, kB4, kB4-CEA205 and CMV promoters,
respectively. TP protein and enzyme activity were detected at comparable levels in kB4-CEA205- and CMV-driven TP cDNA-
transfected cancer cell lines (H630 and RKO). The kB4-TP and CEA205-TP-transfected cell lines, respectively, only demonstrated
negligible and low levels of TP protein and enzyme activity. Both CMV- and kB4-CEA205-driven TP cDNA transiently transfected cells
were 8- to 10-fold sensitised to 5-fluorouracil (5-FU) prodrug, 50-deoxy-5-fluorouradine (50-DFUR), in contrast to only 1.5- to 2-fold
sensitised by the kB4- and CEA205-driven TP cDNA-transfected cells. The bystander killing effect of CMV- and kB4-CEA205-driven
TP cDNA-transfected cells was comparable. This is the first report that indicates that the NF-kB DNA-binding site could be used as a
novel cancer-specific enhancer to improve cancer-specific promoter activity in gene-directed enzyme prodrug therapy.
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Lack of selectivity for malignant cells leading to dose-limiting
toxicity is one of the major obstacles for the success of cancer
chemotherapy. Gene-directed enzyme prodrug therapy (GDEPT) is
potentially an elegant way to improve the therapeutic index of
active anticancer drugs, but one of the major limitations for the
clinical application of this approach is the lack of strong cancer-
specific promoters (Aghi et al, 2000; Rooseboom et al, 2004).
Carcinoembryonic antigen (CEA) is not expressed in normal
and overexpressed in epithelial cancer cells (Shively and Beatty,
1985). Four cis-acting DNA-binding elements mapped on the CEA
promoter region within 300bp upstream of CEA translation
starting point, especially, the first three elements are essential for
specific CEA transcription (Hauck and Stanners, 1995; Richards
et al, 1995a). Utilisation of the CEA promoter in an adenovirus
vector for cytosine deaminase (CD) gene expression improves the
selectivity of 50-deoxy-5-fluorocytidine (5-DFCR)/5-fluorouracil
(5-FU) conversion in CEA-expressing tumours (Richards et al,
1995a; Lan et al, 1996a). However, the transcriptional activity of
CEA in most cancer cell lines is 10- to 300-fold lower than that of
CMV and RSV viral promoters (Lan et al, 1996b; Ueda et al, 2001).
Even when using adenovirus to deliver CEA promoter-driven suicide
gene in vivo, few reports have demonstrated sufficient antitumour
effects. Although a 2.1-kb CEA enhancer can increase the CEA
promoter activity, it is still highly dependent on the intrinsic level of
CEA expression (Richards et al, 1995b; Nyati et al, 2002). The use of
this CEA enhancer–promoter-based prodrug approach in cells with
low levels of CEA expression cannot induce sufficient CD activity to
convert 5-DFCR to 5-FU other than at very low levels (Richards et al,
1995b). As with other cancer-specific promoters, the low promoter
activity is a major obstacle for using CEA promoter-based prodrug
gene therapy in vivo and in clinical trials.
Nuclear factor-kappa B (NF-kB) (Ephrussi et al, 1985) is a
transcription factor, which is composed of five subunits (p50/p105,
p52/p100, p65 (RelA), RelB and c-Rel) forming hetero- or
homodimers. Nuclear factor-kappa B is normally retained in the
cytoplasm as an inactive complex through the direct binding of the
natural inhibitor of kB( I kB) (Karin, 1999). Nuclear factor-kappa B
can be activated by cytokines, UV radiation, reactive oxygen
species and anticancer drugs (Karin, 1999). All of these stimuli
trigger phosphorylation and degradation of IkB and release NF-kB
homo- or heterodimers, which are then translocated into nucleus
and bound to DNA target site (kB site) to influence downstream
gene expression. kB site is a strong cis-acting enhancer sequence
possessing very weak transcriptional activity on its own. In cells
Revised 6 July 2007; accepted 16 July 2007; published online 7 August
2007
*Correspondence: Dr W Wang; E-mail: w.wang2@wlv.ac.uk
British Journal of Cancer (2007) 97, 745–754
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swith high NF-kB activity, kB enhancer specifically magnifies
relevant promoter activity in a cis-acting manner (Ephrussi et al,
1985; Nelms et al, 1990). In a reporter vector, the enhancing
activity of NF-kB can be further improved by multitandem copies
of kB element located upstream of a weak promoter sequence.
Compared with normal cells, most cancer cells possess high NF-kB
activity, which is produced by the cancer cells or the surrounding
inflammatory cells. The NF-kB activity in tumour tissues can be
further induced by exposure to anticancer drugs, radiation or
cytokines (Wang and Cassidy, 2003; Wang et al, 2003).
Capecitabine (CAP), a prodrug of 5-FU (Malet-Martino and
Martino, 2002; Petty and Cassidy, 2004), has been approved as a
first line therapeutic agent for colorectal cancer (CRC) chemo-
therapy. Capecitabine is converted into 5-FU in vivo by a three-
enzyme-catalysed process. Capecitabine is converted to 50-DFCR
and then to 50-deoxy-5-fluorouradine (50-DFUR) by carboxylester-
ase and CD, respectively. Both conversions take place in liver and
are not limiting steps for efficient conversion of CAP to 5-FU. The
final and critical step is the conversion of 50-DFUR to 5-FU by
thymidine phosphorylase (TP). In comparison with normal cells,
cancer cells express relatively higher levels of TP. The TP
expression contrast between cancer and normal cells would
potentially enable the enrichment of 5-FU in tumour cells, while
reducing the exposure of normal tissues to 5-FU. However, TP is
only detected in 24–66% (Evans et al, 2002) of CRC. Most tumours
only express moderate levels of TP with 5-FU-resistant tumours
expressing at even lower levels (Boyer et al, 2004). Consequently,
insufficient conversion of 50-DFUR into 5-FU in tumour tissues
becomes the major limitation of CAP-based chemotherapy. Strong
promoters such as CMV have been used to increase CD and TP
expression in cancer cells and demonstrate enhanced cytotoxicity
of 50-DFCR and 50-DFUR in vitro and in vivo (Huber et al, 1994;
Patterson et al, 1995; Evrard et al, 1999; Ciccolini et al, 2001;
Manome et al, 2001). Yet, the lack of specificity of these promoters
limits the clinical development of GDEPT strategies.
Based on our understanding of the molecular biology of cancer,
in this study, we used a non-virus expression system to develop a
strong and highly cancer-specific NF-kB-CEA enhancer–promoter
system (kB4-CEA205), which demonstrated high cancer-specific
transcriptional activity. Transfection of TP cDNA driven by the
NF-kB-CEA enhancer–promoter cassette highly sensitised CRC
cell lines to 50-DFUR in vitro.
MATERIALS AND METHODS
Cell lines and chemicals
The human CRC cell lines HT29, HCT15, HCT116, LoVo, Caco2,
DLD-1 and RKO were obtained from ATCC. H630 were generously
provided by Professor PG Johnston (University of Belfast). Cancer
cell lines were cultured in DMEM medium supplemented with 10%
fetal calf serum (FCS), 50Uml
 1 penicillin and 50mgml
 1
streptomycin. Normal human mammary epithelial cells (HMEC,
Clonetics, Rockland, ME, USA) were cultured in MEGM medium
(Clonetics CC-3051) supplemented with BPE, hEGF, insulin and
hydrocortisone. The human primary endothelial cells (HUVEC,
Clonetics) were cultured in EBM-2 medium (Clonetics CC-3156)
supplemented with hFGF-B, VEGF, hEGF and 2% FCS. The normal
human nasal epithelial cells (HNEpC, PromoCell, Heidelberg,
Germany) were cultured in the AECGM medium with Supplement-
Mix (PromoCell C-39165). The primary cells were subcultured and
maintained according to the instructed culture system from the
suppliers. Human endothelial cell line EAhy926 was kindly
provided by Dr Angel Armesilla (University of Wolverhampton,
UK) and cultured in RPMI 1640 medium supplemented with 10%
FCS, 50Uml
 1 penicillin and 50mgml
 1 streptomycin. Thymine,
thymidine, 50-DFUR and tetrazolium-based semiautomated colori-
metric (MTT) were purchased from Sigma (Dorset, UK).
Construction of luciferase and TP expression vectors
The human CEA promoter cDNA (pDRIVE-hCEA) purchased
from InvivoGen (San Diego, CA, USA) was subcloned by
polymerase chain reaction (PCR). The CEA basal promoter
sequences in this paper are numbered relative to the middle
nucleotide of the first ATG (Schrewe et al, 1990). Two basal CEA
promoter sequences (CEA205:  245 to  41 and CEA421:  421 to
þ1) were used to construct luciferase reporter vectors in
combination with or without NF-kB enhancer elements. As shown
in Figure 1, both basal promoter sequences contain the essential
CEA promoter region. CEA205 and CEA421 covered the first three
and four cis-acting elements, respectively. The BglII and HindIII
restriction sites were introduced into the forward and reverse
primers, respectively. The primers used were as follows (the
underlined: restriction sites). CEA205: forward 50-GCGCAGATCT
GAAAATAGAAGGGAAAAAAG-30 and reverse 50-GCGCAAGCTT
GAGTTCCAGGAACGTTT-30; CEA421: forward 50-GCGCAGATCT
AGAGCATGGGGAGACCCGGGA-30 and reverse 50-GCG
CAAGCTTGGTCTCTGCTGTCTGCTCTGTC-30. The PCR frag-
ments were subcloned downstream of four tandem NF-kB-binding
sites (kB4; 50-GGGAATTTCC-30  4) replacing the TATA-like
promoter fragment into a commercially available pNF-kB-Luc
vector (BD Biosciences, San Jose, CA, USA). To produce the pkB4-
Luc vector without the essential promoter sequence, the TATA-like
promoter sequence was removed by restriction enzyme cutting and
the backbone plasmid DNA was blunt-ended using DNA
polymerase Klenow fragment (Promega, Southampton, UK) and
religated. To produce expression vectors without the NF-kB
enhancer, the kB-binding sites in pkB4-CEA205-Luc and pkB4-
CEA421-Luc were removed and the backbones religated as
described above. Thymidine phosphorylase cDNA (pCMV6-XL5/
TP) was purchased from Origene (Rockville, MD, USA). Thymi-
dine phosphorylase cDNA was subcloned into pcDNA3 (Invitro-
gen, Paisley, UK) using EcoRI/XbaI to develop pcDNA3-TP in
which TP cDNA is under the control of CMV promoter. To develop
TP expression vectors for transient transfection, the luciferase
cDNA in the above luciferase reporter gene expression vectors was
replaced with TP cDNA derived from pcDNA3-TP by HindIII/XbaI
cutting. For stable expression of TP in CRC cell lines, the CEA205-
TP and kB4-CEA205-TP fragments were subcloned into a
pFastBacDual vector (Invitrogen, Paisley, UK) from which the
p10 and polyhedrin promoters have been removed (pFastBac-
DualDpromoter). The integrity of the sequences of the constructs
was verified by DNA sequencing.
TP-activity assay
The TP enzyme activity was assayed using the method published
by Yoshimura et al (1990) with minor modification. Briefly, 10ml
of total protein extracted in RIPA buffer containing 25mM Tris-
HCl, 0.1% SDS, 1% Triton X-100, 0.15 M NaCl, 1mM EDTA and 1 
protease inhibitor mixture (Roche, East Sussex, UK) was mixed
with 90ml of reaction buffer consisting of 10mM thymidine, 10mM
KH2PO4 (pH 7.4). The reaction was incubated at 371C for 2h and
terminated by addition of 400ml of 0.2 N NaOH. The concentration
of thymine converted from thymidine was measured spectro-
photometrically at 300nm. The amount of thymine in the reaction
was calculated from a standard curve plotted from known thymine
concentrations. Thymidine phosphorylase activity was presented
as nmol thymine/mg protein/hour.
Western blot
Total protein was extracted in RIPA buffer. The lysate was
centrifuged for 5min in a microfuge and the supernatants retained.
The protein (200mg/cell line) was electrophoresed through a 10%
SDS-PAGE and transferred to a PVDF membrane (Millipore,
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sHertfordshire, UK) using a semi-dry electrophoretic transfer
chamber (Millipore). Nonspecific binding was blocked by incubat-
ing the membranes for 1h in TBS-T with 5% non-fat milk, which
was also used to dilute primary (TP, Novocastra, Newcastle upon
Tyne, UK, 1:250; CEA, Abcam, Cambridge, UK, 1:2000) and
secondary (Amersham, Little Chalfont, UK; 1:5000) antibodies.
The signal was detected using an ECL Western blotting detection
kit (Amersham), and visualised by exposure to X-ray film.
Total RNA isolation and RT–PCR
Cells (70% confluent) cultured in 25cm flasks were harvested by
trypsinisation. Total RNA was isolated using TRIzol reagent
(Invitrogen, Paisley, UK) according to the manufacturer’s proto-
cols. The CEA mRNA expression levels in different cell lines were
determined using the Access RT–PCR System (Promega, South-
ampton, UK) following the instruction of the supplier. The CEA-
specific primers were designed from human CEA DNA sequence
(GenBank ID: M17303). The forward (50-CGC CAA AAT CAC GCC
AAA TAA TAA-30) and reverse (50-ACC CCA ACC AGC ACT CCA
ATC AT-30) primers were used to amplify a 171bp PCR product.
The human housekeeping gene GAPDH (GenBank ID: XR018317)
was used as the RNA loading control, which was amplified by the
same RT–PCR system using the following primers, forward: 50-
CATGACAACTTTGGTATCGTG-30; reverse: 50-GTGTCGCTGTTG
AAGTCAGA-30. The RT–PCR amplification conditions were
as follows. One cycle at 481C for 45min; 1 cycle at 941C for
2min; 35 cycles at 941C for 30s, 601C for 30s, 721C for 1min; 1
cycle at 721C for 5min. The RT–PCR products were separated on a
1% agarose gel and the bands visualised and photographed under
UV light.
MTT assay
For in vitro cytotoxicity analysis, the overnight-cultured cells
(5000/well in 96-well flat-bottomed microtiter plates) were
constantly exposed to 50-DFUR for 72h and then subjected to a
standard MTT assay as previously described (Plumb et al, 1989).
To test the effect of transient expression of TP on cytotoxicity of
50-DFUR, cells were transiently transfected with TP expression
vectors for 48h and subjected to MTT assay. To determine the
bystander effect, the pcDNA3-TP- or pkB4-CEA205-TP-transfected
cells were mixed with pcDNA3-transfected cells. The whole cell
populations consisted of 0, 5, 10, 20, 40, 60 and 100% TP cDNA
(pcDNA3-TP and pkB4-CEA205-TP)-transfected cells, respec-
tively, were exposed to 50-DFUR and subjected to MTT analysis.
The IC50so f5 0-DFUR were calculated.
In vitro transfection
Stable transfection Colorectal cancer cell lines (1 10
6/well) were
cultured in six-well plates overnight and transfected with
pFastBacDualDpromoter/kB4-CEA205-TP using Lipofectamine
2000 (Invitrogen, Pasley, UK) following the manufacturer’s
instructions. The pFastBacDual empty vector-transfected cells
were used as a negative control. The successfully transfected clones
were selected in G418 (1mgml
 1). After TP enzyme activity
assay and Western blotting analyses, the positive clones were
selected and cultured in G418-containing medium to enlarge the
cell population. Two positive clones were subjected to further
analysis.
Transient transfection H630 and RKO cells (2 10
6/flask) were
cultured in 25cm tissue culture flasks overnight and transfected
with pcDNA3, pcDNA3-TP, pkB4-TP, pCEA205-TP and pkB4-
CEA205-TP using Lipofectamine 2000 following the manufac-
turer’s instruction. After 48h transfection, the transfected cells
were collected and split for MTT, Western blotting and TP activity
assays, respectively.
Luciferase reporter gene assay
All transfections were performed using Lipofectamine transfection
reagent according to the instruction of the manufacturer (Invitro-
gen, Paisley, UK). Briefly, 5 10
4/well cells were cultured in
24-well plates overnight. The luciferase reporter vectors (pkB4-
Luc, pCEA205-Luc, pkB4-CEA205-Luc, pNF-kB-Tal-Luc and pGL3-
Basic; 0.8mgwell
 1) were co-transfected with 0.008mgwell
 1 pSV40-
Renilla DNA, an internal control for normalisation of the
transcriptional activity of the reporter vectors. Forty-eight hours
after transfection, the cells were lysed and luciferase activities were
determined using Dual Luciferase Assay reagents (Promega, South-
ampton, UK) according to the manufacturer’s instructions. The
luciferase activity in each well was normalised to pSV40-Renilla
using the formula of Ln¼L/R (Ln: normalised luciferase activity; L:
luciferase activity reading and R: Renilla activity reading). The Ln
was further standardised by the transcriptional activity of the pGL3-
Basic using the formula of RLU¼Ln/pGL3-basic (RLU: relative
luciferase unit). All transfections were performed in triplicate and all
experiments were repeated at least twice.
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Figure 1 The schematic diagrams of the CEA promoter region and NF-kB enhancer- and CEA promoter-related constructs used in this study. (A) The
promoter region of CEA gene. FP: footprint site; basal CEA promoter region; essential CEA promoter region; arrow: transcriptional starting point; (B) NF-kB
enhancer- and CEA promoter-related constructs. Luc, luciferase cDNA; TP, thymidine phosphorylase cDNA.
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sRESULTS
Background CEA and TP gene expression and the
transcriptional activity of NF-jB in CRC and normal cells
To evaluate the efficacy of NF-kB-CEA enhancer–promoter system
in 50-DFUR prodrug based GDEPT, it is essential to determine the
background status of TP (protein and enzyme activity), CEA
(mRNA and protein) and NF-kB (transcriptional activity) in cancer
and normal cells. In a panel of eight CRC cell lines, only two (LoVo
and HCT116) expressed the 55kDa TP protein at moderate levels
(25%). No TP protein expression was detected in the remaining six
CRC and normal endothelial and epithelial cells (Figure 2A). The TP
enzyme activity levels in the CRC cell lines were consistent with the
TP protein expression levels (Figure 2C). The 180kDa CEA protein
was detected in four CRC cell lines (50%). Although the CEA mRNA
was detected in most of the CRC cell lines (7/8, Figure 2B), it was
only expressed at relatively high levels in three cell lines (LoVo,
Caco2 and HT29) and at very low levels in the other four cell lines
(DLD-1, HCT116, H630 and RKO). In contrast with cancer cell lines,
no CEA protein and mRNA were identified in normal cells (Figure
2A and B). The transcriptional activity of NF-kBi nC R Ca n dn o r m a l
cells was also examined. High NF-kB activity was detected in all
eight CRC cell lines by luciferase assay. In contrast, the normal
human cells only demonstrated negligible background levels of NF-
kB activity (Figure 2D).
The transcriptional activity and specificity derived from
different combinations of CEA basal promoters and NF-jB
enhancer
To improve the transcriptional activity of CEA promoter and
maintaining its cancer-targeting specificity, we took advantage of
the high NF-kB activity in CRC cell lines and designed a novel NF-
kB-CEA chimeric enhancer–promoter system (Figure 1). In this
system, the basal CEA promoter sequences were placed down-
stream of the four directly linked NF-kB DNA-binding sites
(GGGAATTTCC) in tandem (kB4). There are four cis-acting DNA-
binding sites located within  303 to  143 base pairs of the CEA
promoter region. The transcription factors Sp1, Sp1-like and USF
bind to the first three DNA-binding sites and the transcription
factors for the fourth element are still not clear (Hauck and
Stanners, 1995). To develop an optimal enhancer–promoter
system, we firstly compared the transcriptional activity and
specificity of the luciferase reporter vectors driven by the basal
CEA promoter regions covering the first three (CEA205) or four
(CEA421) DNA-binding elements in combination with or without
kB4 enhancer (Figure 1). The transcriptional activities of the kB4
enhancer, CEA basal promoters (CEA205 and CEA421) and
chimeric enhancer–promoter elements (kB4-CEA205 and kB4-
CEA421) were examined in CRC and normal human endothelial
and epithelial cells. As showed in Figure 3A, both CEA205 and
CEA421 basal promoters demonstrated selective transcriptional
activity in all CRC cell lines but not in normal endothelial and
epithelial cells. In combination with kB4, the transcriptional
activity of both CEA205 and CEA421 in cancer cell lines was
enhanced. The kB4 enhancer demonstrated a significantly greater
enhancing effect on the CEA205 promoter than on the CEA421
promoter (Figure 3A). The kB4 enhancer alone showed very low
transcriptional activity in all tested cancer cell lines (Table 1). Only
background transcriptional activity of CEA promoters, kB4
enhancer and the chimeric kB4-CEA enhancer–promoter cassette
was detected in normal cells (Figure 3A and Table 1). Furthermore,
we compared the transcriptional activity of kB4-CEA205 with a
strong SV40 virus promoter. To avoid the transcriptional
interference between the SV40 promoter in pRL3-SV40 and
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jB4-CEA205 enhancer–promoter system improves GDEPT
X Guo et al
748
British Journal of Cancer (2007) 97(6), 745–754 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
spGL3-SV40, the CRC cell lines were singly transfected with pkB4-
CEA205 and pGL3-SV40. Equal amount of protein (10mg) from
each transfection was subjected to luciferase assay. The transcrip-
tional activity of kB4-CEA205 enhancer–promoter system was
highly comparable to that of the strong SV40 virus promoter in
all CRC cell lines (Figure 3B). The SV40 promoter also
demonstrated high transcriptional activity in a panel of seven
normal human cell lines and primary cell cultures. In contrast, the
transcriptional activity of pkB4-CEA205 in normal cells was
negligible (Figure 3C).
50-DFUR cytotoxicity in CRC cell lines transiently
transfected with a TP expression vector
Owing to the strong and cancer-specific transcriptional activity,
the CEA205 promoter and kB4-CEA205 enhancer–promoter
cassette were subjected to further study. In the TP expression
vectors, the TP cDNA was placed under the control of the CMV,
CEA205, kB4-CEA205 or kB4 promoter. Two CRC cell lines (H630
and RKO) with low TP expression were transiently transfected with
pkB4-TP, pCEA205-TP, pkB4-CEA205-TP, pcDNA3-TP or
pcDNA3 empty vector. After 48h transfection, the cells were
harvested and subjected to different analysis. High levels of TP
protein were detected in both pcDNA3-TP- and pkB4-CEA205-TP-
transfected cells. Only very low levels of TP protein were detected
in the pCEA205-TP-transfected cells and no TP protein was
detected by Western blotting analysis in the pcDNA3- and pkB4-
TP-transfected cell lines (Figure 4A). In line with protein
expression levels, the pcDNA3-TP- and pkB4-CEA205-TP-trans-
fected cells also possessed high TP enzyme activity (Figure 4B).
The TP activity and protein expression patterns were highly
consistent one another in the transfected cells. The transiently
transfected cells were then subjected to MTT analysis. In
comparison with the control (pcDNA3 transfected), the pkB4-
CEA205-TP-transfected RKO and H630 cells were 7.6 and 10 times,
respectively, more sensitive to the 50-DFUR-induced cytotoxicity.
The cytotoxicity of 50-DFUR to the pkB4-CEA205-TP- and
pcDNA3-TP-transfected cell lines was comparable. In comparison
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Figure 3 The transcriptional activity and specificity of CEA205 and CEA421 basal promoters in combination with or without kB4 in CRC and normal
human cell cultures. (A) The cells were co-transfected with luciferase expression vectors (pCEA205-Luc, pkB4-CEA205-Luc, pCEA421-Luc, pkB4-CEA421-
Luc and pGL3-Basic) and Renilla expression vector (pRL3-SV40). The luciferase activity of each transfection was normalised by the Renilla reading. The
luciferase activity is represented by the ratio of the specific promoter over the activity of pGL3-Basic. The column represents the mean of three
measurements and the bar represents the s.d. (B and C) The cells were singly transfected with pGL3-SV40- or pkB4-CEA205-Luc and the absolute
luciferase activity in equal amount of protein from different transfections was compared.
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sTable 1 Transcriptional activities of kB4, CEA205 and kB4-CEA205 in CRC and normal cells
LoVo Caco2 H630 HCT116 HCT15 HT29 DLD-1 RKO EAhy926 HUVEC HMEC HNEpC
pkB4-Luc 5.670.7 13.074.5 13.072.7 14.072.1 13.874.0 2.370.7 34.473.4 12.270.3 1.070.5 1.070.08 1.070.08 0.770.003
pCEA205-Luc 20.478.3 31.375.1 31.374.7 101.175.2 72.875.3 11.372.0 191.3718.9 42.072.3 1.170.6 1.170.02 1.170.02 2.370.01
pkB4-CEA205-Luc 180.6723.9 183.9716.9 183.972.6 379.3721.4 558.3783.8 19.676.4 993.6768.1 207.473.8 1.070.003 0.9570.003 0.9570.003 1.870.02
The data represent mean relative luciferase units from three replicates7s.d.
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swith pcDNA3-TP- and pkB4-CEA205-TP-transfected cells, the
pkB4-TP and pCEA205-TP transfection only slightly increased the
cytotoxicity of 50-DFUR to the CRC cell lines (Figure 4C and D and
Table 2).
The bystander effect of pFastBacDualDpromoter/jB4-
CEA205-TP-transfected CRC cells on the neighbouring
cells
To produce cell lines for the bystander effect analysis, the H630
and RKO cell lines were stably transfected with pFastBacDualD
promoter/kB4-CEA205-TP (pFBD/KCT) or pcDNA3-TP. Two
positively transfected clones were selected from each cell line for
further study. The TP protein expression and TP enzyme activity
in the pFBD/KCT-transfected cell lines were high and comparable
with that in the pcDNA3-TP-transfected cells (Figure 5A and B).
Furthermore, the cytotoxicity of 50-DFUR to the pcDNA3-TP and
pFBD/KCT stably transfected cell lines was determined by MTT
analysis. The pFBD/KCT stable transfection significantly enhanced
the cytotoxicity of 50-DFUR to both RKO and H630 cell lines (over
28-fold). The IC50so f5 0-DFUR to the pFBD/KCT-transfected cells
were similar to those of pcDNA3-TP-transfected cells (Table 3).
Low transfection rate is still one of the major barriers for the
success of cancer GDEPT in the clinic. It has been reported that the
small portion of CMV promoter-driven TP-transfected cells can
effectively convert 50-DFUR into 5-FU, which can be released and
performed cytotoxic effect onto the neighbouring cells (bystander
effect) (Patterson et al, 1995). Figure 5C and D show that when
pcDNA3-TP- or pFBD/KCT-transfected RKO or H630 cells
composed only 5% of the whole-cell population, the sensitivity
of H630 and RKO cell lines to 50-DFUR was significantly enhanced.
If the percentage of the transfected cells was further increased, the
IC50so f5 0-DFUR in these cells were further reduced but the curves
significantly levelled off. The bystander effect of pFBD/KCT- and
pcDNA3-TP-transfected cells was comparable.
DISCUSSION
As with other cancer-specific promoter systems, low transcrip-
tional activity limits the clinical use of the CEA promoter in
GDEPT. It has been reported that the transcriptional activity of
CEA promoter is significantly improved by multimerisation of the
essential CEA promoter region and/or fusing the CEA promoter
with a CEA enhancer sequence. Although the transcriptional
activity of CEA promoter is significantly improved by these
modifications, all of these approaches are highly cell line and CEA
activity dependent. The transcriptional activity of these modified
promoter systems remains at very low levels in the low CEA-
expressing cancer cells (Richards et al, 1995a; Nyati et al, 2002).
High NF-kB activity is a very common feature of cancers (Rayet
and Gelinas, 1999). In this study, four linked NF-kB-binding sites
in tandem (kB4) were exploited as a cancer-specific enhancer to
improve the transcriptional activity of the CEA promoter. The
enhancing effect of kB4 on the transcriptional activity of two basal
CEA promoters covering the first three (CEA205) and four
(CEA421) DNA-binding sites on the CEA promoter region was
examined. Both promoters demonstrated comparable transcrip-
tional activity, which was further enhanced by kB4 in CRC cell
lines. In comparison with that on CEA421, the kB4 enhancer
demonstrated stronger enhancing effect on CEA205 promoter
(Figure 3A). The luciferase assay showed that the transcriptional
activity of kB4-CEA205 was comparable with that of SV40
promoter (Figure 3B). Similar to other cancer-related genes,
although CEA and NF-kB are highly expressed in cancer cells, the
low levels of both are still detectable in some normal tissues
(Hammarstrom, 1999). Therefore, we also tested the potential
transcriptional leakage of the NF-kB-CEA enhancer–promoter
system. In agreement with a previous report (Perkins et al, 1993),
the NF-kB-binding sites by itself, as an enhancer element, only
possessed very low transcriptional activity. The transcriptional
activity in cancer cell lines was highly increased by the
combination of kB4 and CEA promoter and meanwhile the
cancer-targeting specificity was still remained (Figure 3A and C
and Table 1). Our results demonstrated that kB4 enhancer
efficiently improved the transcriptional activity of CEA basal
promoter without impairing its cancer specificity. The fidelity
of the kB4-CEA205 enhancer–promoter system was therefore
improved by the increased transcriptional contrast between the
cancer and normal cells.
In this study, TP/50-DFUR was used as a model to test the
efficacy of the kB4-CEA205 enhancer–promoter system. Thymi-
dine phosphorylase is a key enzyme for CAP, a 5-FU prodrug
(Malet-Martino and Martino, 2002). As the TP activity in various
cancers is highly heterogeneous, the clinical response of cancer
patients to CAP remains relatively low (Malet-Martino and
Martino, 2002). In this study, the TP protein expression was only
detected in two CRC cell lines. Transient transfection of pkB4-
CEA205-TP and pcDNA3-TP resulted in comparable expression
levels of TP protein in human CRC cell lines. In contrast, the
pCEA205-TP-transfected cells only expressed TP protein at very
low levels. The TP protein expression in these cell lines was
reflected by the TP activity assay results. These results indicated
that the transcriptional efficacy of kB4-CEA205 was comparable
with that of CMV strong virus promoter. In line with the TP
protein and enzyme activity results, the MTT assay demonstrated
that the cytotoxicity of 50-DFUR to H630 and RKO cell lines was
highly sensitised by the transfection of pcDNA3/TP or pkB4-
CEA205-TP (7.6 to 14.5-fold, Figure 4C and D and Table 2).
One of the major limitations for the clinical application of
GDEPT is the low transfection rate in vivo, which can be overcome
by bystander effect. Using strong virus promoters, it has been
reported that the 5-FU derived from 50-DFUR can diffuse from the
transfected cancer cells to exert bystander killing effect on their
neighbour cells in a gap junction-independent manner (Patterson
et al, 1995; Kato et al, 1997). In this study, we also compared the
bystander effect of pFBD/KCT- and pcDNA3/TP-transfected cancer
cell lines. Figure 5C and D shows that the cytotoxicity of 50-DFUR
to RKO and H630 cell lines was significantly enhanced by the
mixture of only 5% of pcDNA3/TP- or pFBD/KCT-transfected
cells. The bystander effect was levelled off when further increasing
the TP-transfected cells in the mixture. As well, the bystander
effect of pcDNA3/TP and pFBD/KCT transfection was very similar
in both cell lines.
The molecular mechanisms of enhancing effect of kB4 on CEA
promoter activity in this study were still not clear. Although by
definition, enhancer is a DNA element, which efficiently regulates
promoter activity distantly and orientation-independently (Banerji
et al, 1983; Sassone-Corsi et al, 1983), the relationship between
enhancer and promoter elements is far more complex. A
cooperative interaction between NF-kB and Sp1 has been
demonstrated in human immunodeficiency virus long terminal
repeat (HIV-1 LTR) promoter region (Nabel and Baltimore, 1987;
Perkins et al, 1993). The cooperation between NF-kB and Sp1 in
the HIV-1 LTR is highly space and orientation-dependent. The
promoter activity is significantly impaired by the insertion of DNA
Table 2 The cytotoxicity of 50-DFUR on the transiently transfected CRC
cell lines
pcDNA3 pcDNA3/TP pjB4-TP pCEA205-TP pjB4-CEA205-TP
H630 33.473.2 2.371.0 28.371.9 25.170.8 3.371.2
RKO 33.679.1 3.872.5 20.772.5 15.671.1 4.470.2
The data represent the mean IC50 (mm) of 50-DFUR from three replicates7s.d.
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sfragments between the kB- and Sp1-binding sites. Mutation of the
adjacent kB and Sp1 DNA-binding sites completely abolishes the
phorbol myristate acetate inducible transcriptional activity
(Perkins et al, 1993). It was also reported that an Sp1-dependent
promoter is distantly enhanced by an NF-kB enhancer
(Teferedegne et al, 2006). The cooperation between NF-kB and
Sp1 needs direct contact of both proteins and other transcription
modulators (Perkins et al, 1993; Teferedegne et al, 2006).
Chromatin modulation is also involved. Two Sp1 and Sp1-like
DNA-binding sites are located on the CEA promoter region (FP2
and FP3) (Chen et al, 1995; Hauck and Stanners, 1995). Therefore,
the interaction between NF-kB and Sp1 may also play a role in our
kB4-CEA205 enhancer–promoter system. The kB4 enhancer
demonstrated higher enhancing effect on CEA205 than CEA421
in most CRC cell lines (Figure 3A). The distance between the kB4
and the 50 Sp1 in kB4-CEA205 and kB4-CEA421 fragments was
29 and 250nt, respectively. The spatial rule may also partially
apply to the enhancer–promoter systems in this study. Sp1 is a
common element in cancer-specific promoters, for example CEA,
survivin and hTERT (Chen et al, 1995; Hauck and Stanners, 1995;
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Figure 5 The TP protein (A) and enzyme activity (B) levels in the TP cDNA stably transfected cancer cell lines. pFBD/KCT-1 and pFBD/KCT-2:
pFastBacDual/kB4-CEA205-TP clone 1 and clone 2. Vinculin: protein loading control. The bystander killing effect of CMV- or kB4-CEA205-driven TP cDNA
transfection was compared in H630 (C) and RKO (D) cells. The curves were derived from three replicates and the bars represent s.d.
Table 3 The cytotoxicity of 50-DFUR on the stably transfected CRC cell
lines
pFastBacDualDpromoter/jB4-
CEA205-TP
pcDNA3 pcDNA3/TP C1 C2
H630 27.7712.9 0.9470.54 0.9670.02 0.9470.03
RKO 28.3713.2 1.1670.71 0.9070.07 1.0070.06
The data represent the mean IC50 (mm) of 50-DFUR from three replicates7s.d. C1
and C2: clones 1 and 2.
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sLi and Altieri, 1999; Takakura et al, 1999). Our unpublished data
showed that kB4 also improved the transcriptional activity of
hTERT promoter. Therefore, investigation of the relationship
between kB4 and Sp1 might provide evidence for using kB4 to
improve the transcriptional activity of other cancer-specific
promoters.
The lack of strong cancer-specific promoter system remains one
of the major obstacles for the clinical success of GDEPT. This is the
first in vitro study using NF-kB DNA-binding site as a cancer-
specific enhancer element to improve the cancer-specific tran-
scriptional activity of CEA promoter. The in vivo investigation
needs to be carried out to use this enhancer system for GDEPT
approach.
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